TransThera Sciences and Allist Pharmaceuticals Enter Collaboration for Phase II Lung Cancer Clinical Trial
Key Highlights
- Strategic Partnership: TransThera Sciences (Nanjing), Inc. has entered into a clinical trial collaboration and supply agreement with Shanghai Allist Pharmaceuticals Co., Ltd. to jointly advance a novel combination therapy for non-small cell lung cancer (NSCLC).
- Novel Drug Combination: The collaboration will evaluate the combination of TransThera’s TT-00973-MS tablets with Allist’s firmonertinib mesylate tablets in patients with locally advanced or metastatic NSCLC harboring EGFR-sensitive mutations.
- Clinical Trial Details: The multi-center, open-label Phase II study will assess the safety and efficacy of the combination therapy.
- Roles and Investment: TransThera will sponsor and bear all operational and trial costs, while Allist will provide firmonertinib mesylate tablets free of charge for the study.
- Future Potential: Positive results from the Phase II trial could lead to a Phase III collaboration exploring broader clinical and commercial opportunities for the drug combination.
Details for Shareholders
- Drug Innovation: TT-00973 is a first-in-class dual AXL/FLT3 inhibitor developed by TransThera. AXL kinase is implicated in cancer survival, metastasis, and drug resistance, and its aberrant activation is linked to poor prognosis in multiple cancers.
- Clinical Data: Preclinical studies have shown TT-00973 to effectively suppress AXL activation and demonstrate strong anti-tumor activity in animal models. A completed Phase I trial indicated the drug is well-tolerated, with observable responses in solid tumor patients.
- Firmonertinib Advantages: Firmonertinib mesylate is an EGFR tyrosine kinase inhibitor (EGFR-TKI) with proven broad efficacy across multiple EGFR mutations. It is approved and recognized by both China’s NMPA and the US FDA as a breakthrough therapy for various NSCLC indications.
- Regulatory Status: Firmonertinib’s inclusion in the List of Breakthrough Therapy Designation by the NMPA and its Breakthrough Therapy Designation from the US FDA for specific NSCLC indications underscore its clinical promise and global relevance.
- Potential Share Price Impact: This collaboration marks a significant advancement in TransThera’s pipeline and could be price sensitive. Positive clinical results or further regulatory milestones may materially affect the company’s valuation and share price.
Additional Information
- The agreement enables both companies to jointly explore a Phase III trial subject to the success of the current study, potentially accelerating the path to commercialization.
- There is no assurance of final market approval, and investors are cautioned that the products are still under clinical development.
Warning: In accordance with Rule 18A.08(3) of the Listing Rules, there is no guarantee that the relevant products will ultimately be successfully developed and marketed by TransThera Sciences.
Board of Directors
As of the announcement date, the Board consists of Dr. Frank Wu (Chairman and CEO), Mr. Wu Di (Executive Director), Ms. Jia Zhongxin (Non-Executive Director), and independent non-executive directors Mr. Li Shu Pai, Ms. Chui Hoi Yam, and Ms. Zheng Zhelan.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors are advised to make their own assessment and seek professional advice before making any investment decisions. The development and commercialization of pharmaceutical products are subject to significant risk and regulatory uncertainties.
【廣東話版本】
傳世生物與艾力斯藥業達成合作協議 聯手開展肺癌新療法第二期臨床試驗
重點摘要
- 策略合作：傳世生物（南京）股份有限公司與上海艾力斯藥業股份有限公司簽訂臨床試驗合作及供應協議，聯手開發非小細胞肺癌（NSCLC）新組合療法。
- 創新藥物組合：本次合作將評估TT-00973-MS片與艾力斯的福莫替尼甲磺酸片聯合用於帶有EGFR敏感突變的局部晚期或轉移性NSCLC患者。
- 臨床試驗詳情：雙方將開展多中心、開放標籤的第二期臨床試驗，評估組合療法的安全性及有效性。
- 分工與資金：傳世生物作為試驗的發起方，負責全部運營及試驗費用，艾力斯則免費提供福莫替尼甲磺酸片。
- 未來潛力：如二期臨床取得積極成果，雙方將進一步探討三期臨床合作，加快推動產品上市。
股東須知
- 藥物創新：TT-00973為傳世生物自主研發的首創雙靶點AXL/FLT3抑制劑。AXL激酶在腫瘤存活、轉移及耐藥中發揮關鍵作用，其異常激活與多種癌症的不良預後相關。
- 臨床數據：前期動物實驗顯示TT-00973能有效抑制AXL激活，具有顯著抗腫瘤活性。第一期臨床已完成，藥物耐受性良好，部分實體瘤患者出現有效反應。
- 福莫替尼優勢：福莫替尼甲磺酸片屬於EGFR酪氨酸激酶抑制劑，對多種EGFR突變均有廣泛療效，並獲中國藥監局（NMPA）及美國FDA突破性療法認定。
- 監管狀態：福莫替尼多項適應症被列入NMPA突破性療法名單，並獲美國FDA突破性療法資格，彰顯其臨床前景及全球影響力。
- 潛在股價影響：本次合作標誌著公司管線的重要進展，屬於具價格敏感訊息。臨床結果或監管里程碑有機會顯著影響公司估值及股價。
其他資料
- 協議允許雙方根據二期試驗結果共同推進三期臨床，有望加速產品商業化進程。
- 產品尚處於臨床開發階段，最終能否上市仍具不確定性，投資者需審慎評估。
警告：根據上市規則第18A.08(3)條，並不能保證有關產品最終可成功開發及上市。
董事會資料
截至公告日，董事會成員包括：董事長兼CEO吳鵬博士，執行董事吳迪女士，非執行董事賈仲新女士，以及獨立非執行董事李樹培先生、徐海欣女士和鄭哲蘭女士。
免責聲明：本文僅供參考，並不構成任何投資建議。投資者應自行判斷並尋求專業意見，生物醫藥產品的開發和商業化存在重大風險及監管不確定性。
